{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T08:41:01Z","timestamp":1777797661048,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.hroo.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:32:00Z","timestamp":1636849920000},"page":"40-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dose-limiting, adverse event\u2013associated bradycardia with \u03b2-blocker treatment of atrial fibrillation in the GENETIC-AF trial"],"prefix":"10.1016","volume":"3","author":[{"given":"William T.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dufton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Aleong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Rienstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia P.","family":"Huebler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2021.11.005_bib1","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.11.005_bib2","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.11.005_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","article-title":"Treatment of chronic heart failure with \u03b2-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology","volume":"109","author":"Bristow","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.hroo.2021.11.005_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2006.01.015","article-title":"Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study","volume":"8","author":"Van Veldhuisen","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jchf.2013.04.002","article-title":"Prevention of atrial fibrillation by bucindolol is dependent on the beta\u2081389 Arg\/Gly adrenergic receptor polymorphism","volume":"1","author":"Aleong","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib6","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"38","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.11.005_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jchf.2014.01.005","article-title":"Is heart rate important for patients with heart failure in atrial fibrillation?","volume":"2","author":"Cullington","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/clc.22725","article-title":"Heart rate and outcome in heart failure with reduced ejection fraction: differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis","volume":"40","author":"Mulder","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hroo.2021.11.005_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/pace.13030","article-title":"Sinus node dysfunction and atrial fibrillation: a reversible phenomenon?","volume":"40","author":"Jackson","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.11.005_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.amjcard.2012.06.037","article-title":"Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation","volume":"110","author":"Barrett","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.11.005_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2125.1994.tb04238.x","article-title":"Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity","volume":"37","author":"Channer","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hroo.2021.11.005_bib12","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/01.CIR.89.4.1632","article-title":"Dose-response of chronic \u03b2-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy","volume":"89","author":"Bristow","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.11.005_bib13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.11.005_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.106.666016","article-title":"Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial","volume":"116","author":"Colucci","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.11.005_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2019.04.004","article-title":"Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population","volume":"7","author":"Piccini","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib16","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A polymorphism within a highly conserved \u03b21-adrenergic receptor motif alters \u03b2-blocker response in multiple models and human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hroo.2021.11.005_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(03)00044-8","article-title":"An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study","volume":"5","author":"White","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009591","article-title":"Bucindolol decreases atrial fibrillation burden in patients with heart failure and the ADRB1 Arg389Arg genotype [published online ahead of print]","author":"Piccini","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hroo.2021.11.005_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/eurjhf\/hfs181","article-title":"Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation","volume":"15","author":"Kao","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib20","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/ejhf.1970","article-title":"Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP-HF study","volume":"22","author":"Van Veldhuisen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2021.11.005_bib21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa012630","article-title":"Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents","volume":"346","author":"Lowes","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.11.005_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/01.CIR.80.6.1675","article-title":"Diverse mechanisms of unexpected cardiac arrest in advanced heart failure","volume":"80","author":"Luu","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.11.005_bib23","first-page":"65","article-title":"Beneficial effects of bucindolol in a canine model of pentobarbital-induced heart failure","volume":"250","author":"Deitchman","year":"1981","journal-title":"Arch Int Pharmacodyn Ther"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821002154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821002154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:24:32Z","timestamp":1762993472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501821002154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666501821002154"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2021.11.005","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-limiting, adverse event\u2013associated bradycardia with \u03b2-blocker treatment of atrial fibrillation in the GENETIC-AF trial","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}